ZA200502650B - Remedies or preventives for urinary frequency or urinary incontinence and morphinan derivatives having nitrogencontaining heterocyclic group - Google Patents
Remedies or preventives for urinary frequency or urinary incontinence and morphinan derivatives having nitrogencontaining heterocyclic group Download PDFInfo
- Publication number
- ZA200502650B ZA200502650B ZA200502650A ZA200502650A ZA200502650B ZA 200502650 B ZA200502650 B ZA 200502650B ZA 200502650 A ZA200502650 A ZA 200502650A ZA 200502650 A ZA200502650 A ZA 200502650A ZA 200502650 B ZA200502650 B ZA 200502650B
- Authority
- ZA
- South Africa
- Prior art keywords
- fused ring
- hydrogen
- hydroxy
- substituted
- bound
- Prior art date
Links
- INAXVFBXDYWQFN-XHSDSOJGSA-N morphinan Chemical class C1C2=CC=CC=C2[C@]23CCCC[C@H]3[C@@H]1NCC2 INAXVFBXDYWQFN-XHSDSOJGSA-N 0.000 title claims description 26
- 206010036018 Pollakiuria Diseases 0.000 title claims description 22
- 206010046543 Urinary incontinence Diseases 0.000 title claims description 22
- 208000022934 urinary frequency Diseases 0.000 title claims description 22
- 230000036318 urination frequency Effects 0.000 title claims description 22
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 title claims description 18
- 125000000623 heterocyclic group Chemical group 0.000 title claims description 13
- 229940051807 opiod analgesics morphinan derivative Drugs 0.000 title description 6
- 230000003449 preventive effect Effects 0.000 title description 2
- -1 trifluoromethoxy, cyano, isothiocyanato Chemical group 0.000 claims description 180
- 239000001257 hydrogen Substances 0.000 claims description 111
- 229910052739 hydrogen Inorganic materials 0.000 claims description 111
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 96
- 150000002431 hydrogen Chemical class 0.000 claims description 89
- 125000000217 alkyl group Chemical group 0.000 claims description 55
- 125000004432 carbon atom Chemical group C* 0.000 claims description 41
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 40
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 39
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 37
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 33
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims description 30
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 claims description 30
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 27
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 27
- 125000003545 alkoxy group Chemical group 0.000 claims description 22
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims description 20
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 20
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 claims description 20
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 claims description 20
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 19
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 18
- 239000002253 acid Substances 0.000 claims description 18
- 125000003118 aryl group Chemical group 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 18
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 17
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 17
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 17
- 229910052794 bromium Inorganic materials 0.000 claims description 17
- 239000000460 chlorine Substances 0.000 claims description 17
- 229910052801 chlorine Inorganic materials 0.000 claims description 17
- 230000000069 prophylactic effect Effects 0.000 claims description 17
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 17
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 16
- 239000011737 fluorine Substances 0.000 claims description 16
- 229910052731 fluorine Inorganic materials 0.000 claims description 16
- 230000001225 therapeutic effect Effects 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 125000003342 alkenyl group Chemical group 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 14
- 125000004423 acyloxy group Chemical group 0.000 claims description 13
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
- 125000001424 substituent group Chemical group 0.000 claims description 13
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 229910052717 sulfur Chemical group 0.000 claims description 12
- 150000001721 carbon Chemical group 0.000 claims description 11
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 10
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 10
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 claims description 10
- ZXIJMRYMVAMXQP-UHFFFAOYSA-N cycloheptene Chemical compound C1CCC=CCC1 ZXIJMRYMVAMXQP-UHFFFAOYSA-N 0.000 claims description 10
- 125000001810 isothiocyanato group Chemical group *N=C=S 0.000 claims description 10
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 10
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 10
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 claims description 9
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 9
- 125000005336 allyloxy group Chemical group 0.000 claims description 8
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 8
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 8
- 125000004434 sulfur atom Chemical group 0.000 claims description 8
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 6
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 claims description 6
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 6
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000001301 oxygen Chemical group 0.000 claims description 6
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- 150000003457 sulfones Chemical class 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 125000004344 phenylpropyl group Chemical group 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 150000003462 sulfoxides Chemical class 0.000 claims description 2
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims description 2
- 206010027566 Micturition urgency Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 9
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000011321 prophylaxis Methods 0.000 description 5
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 4
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 4
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 4
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 4
- 125000001153 fluoro group Chemical group F* 0.000 description 4
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 4
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 4
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 239000011593 sulfur Chemical group 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 206010046555 Urinary retention Diseases 0.000 description 2
- 230000001078 anti-cholinergic effect Effects 0.000 description 2
- UZBQIPPOMKBLAS-UHFFFAOYSA-N diethylazanide Chemical compound CC[N-]CC UZBQIPPOMKBLAS-UHFFFAOYSA-N 0.000 description 2
- QKIUAMUSENSFQQ-UHFFFAOYSA-N dimethylazanide Chemical compound C[N-]C QKIUAMUSENSFQQ-UHFFFAOYSA-N 0.000 description 2
- 206010013663 drug dependence Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 150000003016 phosphoric acids Chemical class 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 150000003892 tartrate salts Chemical class 0.000 description 2
- 125000003944 tolyl group Chemical group 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical class O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical class C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- 235000011777 Corchorus aestuans Nutrition 0.000 description 1
- 240000004792 Corchorus capsularis Species 0.000 description 1
- 235000010862 Corchorus capsularis Nutrition 0.000 description 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000028257 Joubert syndrome with oculorenal defect Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical class OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 150000008107 benzenesulfonic acids Chemical class 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000001734 carboxylic acid salts Chemical class 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 229960003064 flavoxate hydrochloride Drugs 0.000 description 1
- XOEVKNFZUQEERE-UHFFFAOYSA-N flavoxate hydrochloride Chemical compound Cl.C1=CC=C2C(=O)C(C)=C(C=3C=CC=CC=3)OC2=C1C(=O)OCCN1CCCCC1 XOEVKNFZUQEERE-UHFFFAOYSA-N 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical class OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- AQYSYJUIMQTRMV-UHFFFAOYSA-N hypofluorous acid Chemical compound FO AQYSYJUIMQTRMV-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 150000004701 malic acid derivatives Chemical class 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 230000036453 micturition reflex Effects 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- HWMFFWCDLWDYGX-UHFFFAOYSA-N n-(4-aminophenyl)furan-2-carboxamide Chemical compound C1=CC(N)=CC=C1NC(=O)C1=CC=CO1 HWMFFWCDLWDYGX-UHFFFAOYSA-N 0.000 description 1
- 229960005434 oxybutynin Drugs 0.000 description 1
- 150000003021 phthalic acid derivatives Chemical class 0.000 description 1
- 229960001187 propiverine hydrochloride Drugs 0.000 description 1
- 238000004793 spatially offset Raman spectroscopy Methods 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
- C07D489/08—Oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002295616 | 2002-10-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200502650B true ZA200502650B (en) | 2006-06-28 |
Family
ID=32089217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200502650A ZA200502650B (en) | 2002-10-09 | 2005-04-01 | Remedies or preventives for urinary frequency or urinary incontinence and morphinan derivatives having nitrogencontaining heterocyclic group |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7320984B2 (es) |
| EP (1) | EP1555266B1 (es) |
| JP (1) | JP4016986B2 (es) |
| KR (1) | KR101060629B1 (es) |
| CN (1) | CN100537573C (es) |
| AU (1) | AU2003272944B2 (es) |
| BR (1) | BR0314754A (es) |
| CA (1) | CA2501389C (es) |
| ES (1) | ES2479042T3 (es) |
| HK (1) | HK1079786B (es) |
| IL (1) | IL166944A (es) |
| MA (1) | MA27454A1 (es) |
| MX (1) | MXPA05003723A (es) |
| NO (1) | NO20052167L (es) |
| NZ (1) | NZ539199A (es) |
| WO (1) | WO2004033457A1 (es) |
| ZA (1) | ZA200502650B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060177381A1 (en) * | 2002-02-15 | 2006-08-10 | Howard Brooks-Korn | Opiopathies |
| GB0210397D0 (en) * | 2002-05-07 | 2002-06-12 | Ferring Bv | Pharmaceutical formulations |
| KR101233289B1 (ko) * | 2004-03-30 | 2013-02-14 | 도레이 카부시키가이샤 | 지양제 |
| AR053098A1 (es) | 2004-11-04 | 2007-04-25 | Toray Industries | Analgesico derivado de morfinano |
| JPWO2006104280A1 (ja) * | 2005-03-31 | 2008-09-11 | 武田薬品工業株式会社 | 糖尿病の予防・治療剤 |
| ES2464593T3 (es) | 2005-11-09 | 2014-06-03 | Toray Industries, Inc. | Agente terapéutico o profiláctico para trastornos funcionales digestivos |
| US8106065B2 (en) * | 2005-12-21 | 2012-01-31 | Toray Industries, Inc. | Antitussive agent |
| CA2687955C (en) | 2007-05-21 | 2015-06-30 | Toray Industries, Inc. | Crystalline micropowder particles |
| CA2687956C (en) | 2007-05-21 | 2015-03-31 | Toray Industries, Inc. | Method for producing pharmaceutical tablet |
| RU2472539C2 (ru) | 2007-08-06 | 2013-01-20 | Аллерган, Инк. | Способы и устройства для доставки препарата десмопрессина |
| LT2712622T (lt) * | 2008-05-21 | 2016-09-26 | Ferring B.V. | Burnoje disperguojamas desmopresinas, skirtas nikturijos netrikdomo miego pirminio periodo pailginimui |
| US20100286045A1 (en) | 2008-05-21 | 2010-11-11 | Bjarke Mirner Klein | Methods comprising desmopressin |
| US11963995B2 (en) | 2008-05-21 | 2024-04-23 | Ferring B.V. | Methods comprising desmopressin |
| JP5648480B2 (ja) * | 2008-10-24 | 2015-01-07 | 東レ株式会社 | ４，５−エポキシモルヒナン誘導体を含有する安定な錠剤 |
| WO2010083384A2 (en) * | 2009-01-16 | 2010-07-22 | Virginia Commonwealth University | Non-peptidyl, potent, and selective mu opioid receptor antagonists |
| US8623888B2 (en) * | 2009-07-15 | 2014-01-07 | Mallinckrodt Llc | 3-oxy-hydromorphone derivatives |
| EP2995614B8 (en) | 2010-06-11 | 2018-03-28 | Rhodes Technologies Inc. | Transition metal-catalyzed processes for the preparation of n-allyl compounds and use thereof |
| EP3458061B1 (en) * | 2016-05-19 | 2023-01-18 | Virginia Commonwealth University | Potent and selective mu opioid receptor modulators |
| AU2019229892A1 (en) | 2018-03-08 | 2020-09-03 | University Of Kansas | Treatment of demyelinating diseases |
| CN109970747B (zh) * | 2019-05-05 | 2020-07-24 | 潍坊科技学院 | 一种制备10α-羟基纳呋拉啡的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3318885A (en) * | 1965-07-21 | 1967-05-09 | American Cyanamid Co | Substituted 6-amino-6, 14-endoethen-ocodides and morphides |
| JP2525552B2 (ja) * | 1992-01-23 | 1996-08-21 | 東レ株式会社 | モルヒナン誘導体および医薬用途 |
| CA2143864C (en) | 1993-07-23 | 2006-01-24 | Hiroshi Nagase | Morphinan derivatives and pharmaceutical use thereof |
| AU5090796A (en) * | 1995-03-03 | 1996-09-23 | Algos Pharmaceutical Corporation | Use of dextromethorphan or dextrorphan for the treatment of urinary incontinence |
| EP1203771A4 (en) * | 1999-07-19 | 2003-07-30 | Toray Industries | HEALING OR PREVENTIVE AGENTS FOR THE TREATMENT OF FREQUENCY OF URINATION AND CONTINUITY |
| WO2002080918A1 (fr) * | 2001-04-02 | 2002-10-17 | Toray Industries, Inc. | Agent therapeutique ou prophylactique en cas de miction frequente ou d'incontinence urinaire |
-
2003
- 2003-10-08 WO PCT/JP2003/012890 patent/WO2004033457A1/ja active Application Filing
- 2003-10-08 CN CNB2003801009713A patent/CN100537573C/zh not_active Expired - Fee Related
- 2003-10-08 AU AU2003272944A patent/AU2003272944B2/en not_active Ceased
- 2003-10-08 KR KR1020057006096A patent/KR101060629B1/ko not_active IP Right Cessation
- 2003-10-08 BR BR0314754-1A patent/BR0314754A/pt not_active Application Discontinuation
- 2003-10-08 NZ NZ539199A patent/NZ539199A/en not_active IP Right Cessation
- 2003-10-08 ES ES03754030.9T patent/ES2479042T3/es not_active Expired - Lifetime
- 2003-10-08 MX MXPA05003723A patent/MXPA05003723A/es active IP Right Grant
- 2003-10-08 US US10/530,664 patent/US7320984B2/en not_active Expired - Fee Related
- 2003-10-08 EP EP03754030.9A patent/EP1555266B1/en not_active Expired - Lifetime
- 2003-10-08 JP JP2004542845A patent/JP4016986B2/ja not_active Expired - Fee Related
- 2003-10-08 CA CA2501389A patent/CA2501389C/en not_active Expired - Fee Related
-
2005
- 2005-02-16 IL IL166944A patent/IL166944A/en not_active IP Right Cessation
- 2005-04-01 ZA ZA200502650A patent/ZA200502650B/en unknown
- 2005-04-13 MA MA28218A patent/MA27454A1/fr unknown
- 2005-05-03 NO NO20052167A patent/NO20052167L/no not_active Application Discontinuation
- 2005-12-29 HK HK05112093.6A patent/HK1079786B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| MA27454A1 (fr) | 2005-07-01 |
| JPWO2004033457A1 (ja) | 2006-04-27 |
| BR0314754A (pt) | 2005-07-26 |
| CN1703415A (zh) | 2005-11-30 |
| HK1079786A1 (en) | 2006-04-13 |
| CA2501389A1 (en) | 2004-04-22 |
| NO20052167L (no) | 2005-06-16 |
| US7320984B2 (en) | 2008-01-22 |
| ES2479042T3 (es) | 2014-07-23 |
| EP1555266B1 (en) | 2014-05-21 |
| EP1555266A4 (en) | 2006-12-06 |
| KR101060629B1 (ko) | 2011-08-31 |
| NZ539199A (en) | 2008-09-26 |
| AU2003272944B2 (en) | 2009-11-12 |
| US20060040970A1 (en) | 2006-02-23 |
| MXPA05003723A (es) | 2005-09-30 |
| HK1079786B (zh) | 2010-03-12 |
| CA2501389C (en) | 2013-01-08 |
| CN100537573C (zh) | 2009-09-09 |
| WO2004033457A1 (ja) | 2004-04-22 |
| AU2003272944A1 (en) | 2004-05-04 |
| EP1555266A1 (en) | 2005-07-20 |
| KR20050056232A (ko) | 2005-06-14 |
| JP4016986B2 (ja) | 2007-12-05 |
| IL166944A (en) | 2010-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200502650B (en) | Remedies or preventives for urinary frequency or urinary incontinence and morphinan derivatives having nitrogencontaining heterocyclic group | |
| CA2561509C (en) | Anti-itching agent | |
| US9932349B2 (en) | 8-carboxamido-2,6-methano-3-benzazocines | |
| WO2018188641A1 (zh) | 一种mor激动剂与kor激动剂的药物组合物及其用途 | |
| ZA200204557B (en) | Carbamate derivatives having muscarinic receptor antagonist activity. | |
| CA3093405A1 (en) | Small molecule degraders of polybromo-1 (pbrm1) | |
| CA2586181C (en) | Analgesic | |
| JPWO2005080322A1 (ja) | フルオレン誘導体 | |
| AU2006328765B2 (en) | Antitussive agent | |
| MXPA05005580A (es) | Derivados de isoindolina. | |
| CA3147105A1 (en) | Combination of an a2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea | |
| CA2787323A1 (en) | Therapeutic or prophylactic agent for biliary tract diseases | |
| US20080161419A1 (en) | Prophylactic Antimigraine Agents | |
| CA2628971C (en) | Therapeutic or prophylactic agent for functional bowel disorder | |
| WO2011143444A2 (en) | Diphenylbutypiperidine autophagy inducers | |
| US20080171788A1 (en) | Medicament For Irritable Bowel Syndrome | |
| CA2492694A1 (en) | Therapeutic or prophylactic agent for preventing nausea and vomiting | |
| KR20050107756A (ko) | 종양 억제 활성을 갖는 캄토테신의 7-이미노 유도체 | |
| AU6020300A (en) | Remedies or preventives for frequent urination or urinary incontinence | |
| WO2024079072A1 (en) | New n-heteroarylbenzamides derivatives as flt3 inhibitors | |
| MXPA06011103A (es) | Agente anti-comezon | |
| CN114656480A (zh) | 噻吩并嘧啶类化合物、异构体或盐及其制备方法和用途 | |
| JPH06306076A (ja) | ベンズアミド誘導体 |